Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 200 mg hard capsules REYATAZ 300 mg hard capsules · Abschnitt 4.5 · PDF-Seite 17

HOS-112090 · Präparat HOS-093615

The decrease in AUC, Cmax, and Cmin was not mitigated when an increased dose of REYATAZ/ritonavir (400/100 mg once daily) was temporally separated from omeprazole by 12 hours. Although not studied, similar results are expected with other proton pump inhibitors. This decrease in atazanavir exposure might negatively impact the efficacy of atazanavir. The mechanism of interaction is decreased solubility of atazanavir as intra-gastric pH increases with proton pump inhibitors. Antacids Antacids and medicinal Reduced plasma concentrations of REYATAZ should be administered products containing buffers atazanavir may be the consequence of 2 hours before or 1 hour after increased gastric pH if antacids, including antacids or buffered medicinal buffered medicinal products, are products. administered with REYATAZ. ALPHA 1-ADRENORECEPTOR ANTAGONIST Alfuzosin Potential for increased alfuzosin Co-administration of alfuzosin with concentrations which can result in REYATAZ is contraindicated hypotension. The mechanism of (see section 4.3) interaction is CYP3A4 inhibition by REYATAZ and/or ritonavir. ANTICOAGULANTS Direct-acting oral anticoagulants (DOACs) Apixaban Potential for increased apixaban and Co-administration of apixaban or Rivaroxaban rivaroxaban concentrations which can rivaroxaban and REYATAZ with result in a higher risk of bleeding. ritonavir is not recommended.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) rivaroxaban (HOS-086236) apixaban (HOS-112091) ritonavir (HOS-084521) omeprazole (HOS-085912)